Supports protection against UVA & UVB rays during daily exposure
Abdel Aziz MT, Mostafa T, Atta H, Wassef MA, Fouad HH, Rashed LA, et al
Open communication with your healthcare provider about symptom timing and severity helps determine whether adjustments to your treatment approach are needed
The evidence base for GLP-1 receptor agonists specifically treating binge eating disorder (BED) remains limited but emerging
They help gather evidence related to severe side effects, such as gastroparesis, and work to ensure that drug manufacturers, including Novo Nordisk and Eli Lilly, are held accountable
This review aims to familiarize anaesthetists with these novel drug classes and to present current recommendations from professional organisations